High-Dose Isoniazid Lacks EARLY Bactericidal Activity Against Isoniazid-resistant Tuberculosis Mediated by katG Mutations: A Randomized, Phase 2 Clinical Trial.

Kamunkhwala GausiElisa H IgnatiusVeronique De JagerCaryn UptonSoyeon KimAshley McKhannLaura MoranLubbe WiesnerFlorian von Groote-BidlingmaierPhilip MarzinekNaadira VankerJoseph YvetotSamuel PierreSusan L RosenkranzSusan SwindellsAndreas H DiaconEric L NuermbergerPaolo Denti Kelly E Dooleynull null

Published in: American journal of respiratory and critical care medicine (2024)

gov, ID: NCT01936831.

Keyphrases

mycobacterium tuberculosis
high dose
clinical trial
pulmonary tuberculosis
low dose
stem cell transplantation
phase ii
open label
study protocol
phase iii
hepatitis c virus
human immunodeficiency virus
hiv infected
antiretroviral therapy